The primary function of myeloid-derived suppressor cells (MDSCs) is reflected in their immune modulatory role in several immune-mediated diseases. In immunoglobulin G4 (IgG4)-related disease (IgG4-RD), it has been hypothesized that there are selective regulatory defects that lead to a T helper 2 (Th2) bias immune response. Herein we have taken advantage of a large cohort of patients with IgG4-related sclerosing cholangitis (IgG4-SC), the most common extrapancreatic involvement of IgG4-RD, as well as controls consisting of primary sclerosing cholangitis, autoimmune hepatitis, and healthy volunteers, to study MDSCs. We report dramatically increased levels of receptor activator for nuclear factor kappa B ligand (RANKL) expression in serum and liver from patients with IgG4-SC compared to both liver-disease and healthy controls. 
biliary manifestations and pathogenesis of IgG4-SC remain enigmatic. (1) In general, an antigen-driven immune response is proposed to drive both B-cell commitment to IgG4 production and secretion of proinflammatory and profibrotic cytokines by activated T lymphocytes. (2, 3) It has been hypothesized that there are selective regulatory defects that lead to a T helper 2 (Th2) bias in IgG4-SC. The cytokine profile of IgG4-SC is represented by Th2-type cytokines, including interleukin 4 (IL-4) and IL-13, and T cell-regulatory cytokines, including transforming growth factor beta and IL-10, (4) which are implicated in biliary damage (5) and development of fibrosis. (6) The involvement of additional cytokine pathways and of different cell lineages has also been suggested.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that suppress immune responses through secretion of arginase 1 and inducible nitride oxide (NO) synthase (iNOS) (8) and have been proposed to play key roles in neoplasia, (9) chronic hepatitis B, (10) autoimmunity, (11, 12) and autoimmune liver disease, as reported by our group. (13) In human peripheral blood mononuclear cells (PBMCs), MDSCs include two major subsets, based on their phenotypic and morphological features and defined as polymorphonuclear MDSCs (8, 14) Receptor activator for nuclear factor kappa B (RANK) ligand (RANKL), as a member of the tumor necrosis factor alpha superfamily, possesses proinflammatory properties that were originally identified as key to the regulation of lymphoid tissue formation and dendritic cell function. (15) Activated B lymphocytes have been suggested as a primary source of RANKL in inflamed liver. (16) Recently, it was reported that B cells spontaneously produce RANKL and correspondingly promote osteoclastogenesis and contribute to bone erosion in patients with inflammatory arthritis. (17, 18) It has also been reported that RANKL-producing regulatory T cells promote mammary cancer metastasis through activation of an inhibitor of nuclear factor kappa B (NF-κB) kinase alpha (IκBα), suggesting that targeting RANKL-RANK can potentially modulate cancer metastasis. (19) Other reports have reported anti-inflammatory activity of RANKL. RANKL stimulation of dendritic cells has been associated with oral tolerance induction, (20) and an anti-inflammatory effect was also noted for RANKL-stimulated macrophages. (21) Herein, we aimed to elucidate the role of MDSCs and the mechanism underlying their expansion and activation in the context of IgG4-SC. Due to the difficulties in obtaining fresh liver specimens, we used peripheral blood and well-defined liver biopsy samples from our biobank. In this study, we noted an elevation in the percentage and numbers of peripheral MDSCs in patients with IgG4-SC compared to patients with primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and healthy controls (HC). We also report increased levels of RANKL secreted by B cells, especially by mature plasma cells, and its association with MDSC expansion and immunomodulatory ability.
Materials and Methods

StUDy SUBJeCtS aND SaMpleS
Thirty-one patients with active untreated IgG4-SC with or without autoimmune pancreatitis (type I) were enrolled in Shanghai Renji Hospital. In our study 17 patients with PSC, 30 patients with AIH, as well as 40 HCs were recruited as controls. All control cohorts were age-matched and gender-matched with the IgG4-SC cohort, except that compared with the most common extrapancreatic involvement of IgG4-RD the PSC group were younger. Of the 31 patients diagnosed with IgG4-SC, 5 were at a cirrhotic stage at the time of sample collecting, while the remaining 26 manifested active cholangitis. Based on the cholangiogram of all of the sclerosing cholangitis subjects, the involvement of the bile duct system of 31 patients with IgG4-SC could be divided into intrahepatic (10/31), extrahepatic (6/31), and both intrahepatic and extrahepatic (15/31) . In contrast, the presence of bile duct damage among the PSC patients was 10/17 (intrahepatic), 2/17 (extrahepatic), and 5 (both intrahepatic and extrahepatic). The demographics and clinical parameters are summarized in Supporting Table S1 . Patients with IgG4-SC fulfilled the 2011 comprehensive IgG4-RD diagnostic criteria. (22) PSC patients were diagnosed according to the 2009 European Association for the Study of the Liver Clinical Practice Guidelines "Management of Cholestatic Liver Diseases." (23) None of the patients suffered from neoplasia, including the occurrence of cholangiocarcinoma or pancreatic cancer according to guidelines. (24, 25) Patients with AIH were confirmed by the simplified scoring system for AIH proposed by the International Autoimmune Hepatitis Group. (26) The study was approved by the Shanghai Jiao Tong University ethics committee and performed under the principles of the Declaration of Helsinki.
pBMC iSolatioN aND FloW-CytoMetRiC aNalySiS
Human PBMCs were isolated from freshly obtained blood by gradient centrifugation on FicollHypaque Plus (GE Healthcare). Plasma was collected using ethylene diamine tetraacetic acid as an anticoagulant, aliquoted, and frozen. Multiparametric flow cytometry was used for phenotypic analysis of MDSCs. Monoclonal antibodies specific for the human cell surface markers HLA-DR, CD3, CD11b, CD14, CD15, CD33, chemokine (C-C motif ) receptor 5 (CCR5), and CCR6 were purchased from BD Biosciences; CCR2, chemokine (C-X-C motif ) receptor 3 (CXCR3), and chemokine (C-X3-C motif ) receptor 1 (CX3CR1) monoclonal antibodies were purchased from Biolegend; anti-RANK antibody was purchased from R&D Systems. Phenotypic analysis of all samples was acquired on Fortessa (BD Biosciences) and analyzed using FlowJo (Tree Star). The gating strategy is shown in Supporting Fig. S1A .
eNZyMe-liNKeD iMMUNoSoRBeNt aSSay
RANKL levels in human plasma samples were analyzed using a human soluble RANKL enzyme-linked immunosorbent assay kit (CUSABIO). A 5-fold dilution of all samples was performed before assaying.
iMMUNoHiStoCHeMiCal
StaiNiNg aND CoNFoCal MiCRoSCopy
Formalin-fixed, paraffin-embedded liver tissues from biopsies were used for immunohistochemistry and confocal laser scanning microscopy. Normal liver controls were obtained from adjacent normal tissues in patients who underwent hepatic hemangioma resection. Our procedures for immunohistochemistry and confocal laser scanning microscopy have been described. (27) Briefly, for confocal microscopy, slides were incubated in freshly prepared 3% H 2 O 2 for 10 minutes, then washed in phosphate-buffered saline. After antigen retrieval, sections were incubated with 10% nonimmune goat serum for 30 minutes and then incubated with primary antibodies overnight at 4°C. Samples were incubated with fluorochrome-conjugated secondary antibodies (1:500; Molecular Probes/ Invitrogen) for 30 minutes at 37°C. The nucleus was stained by 4′,6-diamidino-2-phenylindole (Thermo Scientific). Isotype controls were included for all immunostaining assays. Confocal scanning was performed using an LSM-710 laser-scanning confocal microscope (Carl Zeiss, Jena, Germany).
IN VITRO CUltURe
PBMCs were isolated as described above and cultured in Roswell Park Memorial Institute 1640 (RPMI-1640), supplemented with 10% heat-inactivated fetal bovine serum, 10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, 100 U/mL penicillin, 100 μg/mL streptomycin, and 50 mM 2-mercaptoethanol. For the stimulation of MDSCs, granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or IL-6 were added as positive controls. To verify the inductive effect of RANKL, serial concentrations of recombinant human RANKL (R&D Systems) were used and incubated for 7 days. On days 3, 5, and 7, these stimulated PBMCs were collected and prepared for flow cytometry. For signaling pathway analysis, PBMCs were pretreated with inhibitors of the NF-κB pathway including caffeic acid phenethyl ester (CAPE), to effectively suppress the nuclear import of p65 (Selleck), and BAY 11-7082, to inhibit IκBα phosphorylation (Selleck).
iNtRaCellUlaR il-4 aND iNteRFeRoN-gaMMa DeteCtioN
Naive CD4 + T cells were isolated using the Naive CD4 + T Cell Isolation Kit II (Miltenyi, Germany). Th1 polarization and Th2 polarization were alternatively induced under different cytokine combinations as described. (28) For further study of MDSCs' suppressive function, RANKL-induced MDSCs were harvested and sorted by fluorescence-activated cell sorting (FACS) at day 5 of culture and cocultured with naive CD4 + T cells at a ratio of 1:4. The T Cell Activation/Expansion Kit (Miltenyi) was used to achieve T-cell expansion and activation. After 7 days of coculture, cells were treated with phorbol myristate acetate (10 nM) plus ionomycin (1 mM) for 6 hours, as described. (29) Brefeldin A (10 mg/mL) was added for the last 3 hours of culture before cell fixation, permeabilization, and staining using the Human Th1/ Th2/Th17 Phenotyping Kit (BD Biosciences).
ReaCtiVe oXygeN SpeCieS pRoDUCtioN
The oxidation-sensitive chloromethyl derivative of 2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA; Invitrogen) was used to evaluate reactive oxygen species (ROS) production. Cells were incubated at 37°C in RPMI-1640 in the presence of 1 μM CM-H2DCFDA for 30 minutes and then labeled with specific fluorescein-conjugated antihuman antibodies at 4°C for 30 minutes. The ROS content in MDSCs was analyzed by flow cytometry.
DeteCtioN oF No By 4-aMiNo-5-MetHylaMiNo-2′,7′-DiFlUoRoFlUoReSCeiN DiaCetate
4-Amino-5-methylamino-2′,7′-difluorofluorescein (DAF-FM) diacetate was purchased from Molecular Probes. Briefly, flow-cytometric staining of cultured PBMCs was performed as described above. Cells were incubated with dimethyl sulfoxide-diluted DAF-FM diacetate for 30 minutes at 37°C. After washing to remove excess probe, cells were replaced in fresh medium and incubated for another 30 minutes to allow complete deesterification of the intracellular diacetate; NO production in MDSCs was analyzed by flow cytometry.
SUpeRNataNt No pRoDUCtioN
NO content in plasma was measured using the Greiss reaction (Biovision, Milpitas, CA). An equal volume of plasma (100 μL) was mixed with the Greiss reagent and incubated for 10 minutes at room temperature. The absorbance at 550 nm was measured using a microplate plate reader (Bio-Rad, Hercules, CA). Nitrite concentrations were determined by comparing the absorbance values for the test samples to a standard curve generated by serial dilution of 0.25 mM sodium nitrite.
StatiStiCal aNalySiS
All statistical tests were performed using SPSS software (version 22) , and data are presented as mean values ± SEM unless otherwise specified. Statistical differences for normally distributed data were analyzed by the Student t test; all continuous, nonnormally distributed data were analyzed by nonparametric testing. Categorical variables were assessed by chi-square or Fisher's exact test, as appropriate. Correlations were determined using Pearson's correlation coefficient (Pearson's r values for normally distributed data) or Spearman's correlation coefficient (Spearman's rho values for nonparametric data). P < 0.05 was considered significant.
Results
eleVateD leVelS oF RaNKl iN igg4-SC
There was a significant elevation of serum RANKL levels in IgG4-SC (1,258 ± 78.1 pg/mL) compared with PSC (795.6 ± 90.8 pg/mL, P = 0.0006), AIH (881.1 ± 63.4 pg/mL, P = 0.0004), or HCs (303.0 ± 55.1 pg/mL, P < 0.0001) (Fig. 1A) . Strikingly, while RANKL-positive cells were absent in normal liver tissues, there was a predominance of RANKL-positive cells surrounding the damaged interlobular bile ducts in IgG4-SC liver (Fig. 1C) .
There was a correlation of serum IgG4 and IgG with RANKL (Supporting Fig. S1B,C) . Importantly, the levels of plasma RANKL positively correlated with the IgG4/IgG ratio (R 2 = 0.4124, P = 0.0002) (Fig. 1B) , suggesting that secretion of RANKL may be associated with immunoglobulin-producing cells. Subsequently, to validate the cellular source of RANKL in IgG4-SC, we performed immunofluorescence double staining for RANKL and B-cell markers. RANKL colocalized with CD19, CD38, and CD138, especially with the mature plasma marker CD38 (Fig. 1D) Fig. S5A,B) .
MDSCS eXpReSS tHe RaNKl ReCeptoR RaNK
Confocal microscopy was further used to identify the expression of receptor for RANKL, and as expected, the receptor RANK primarily colocalized with myeloid markers CD11b and CD33, suggesting myeloid cells as the target of secreted cytokine RANKL ( Fig. 2A; Supporting Fig. S1E ). The percentage and cell count of MDSCs in the periphery were evaluated by flow cytometry. There was a significant abundance of CD11b + CD33 + HLA-DR
MDSCs in the PBMCs in IgG4-SC compared to HCs (P < 0.0001) or disease controls (PSC and AIH, both P < 0.0001) (Fig. 2B) . Consistent with increased percentages, the absolute number of MDSCs was significantly increased in IgG4-SC (10,648 ± 826.5 cells/mL) compared to PSC (4,542 ± 592.1 cells/mL, P < 0.0001), AIH (3,627 ± 368.5 cells/mL, P < 0.0001), or HCs (1,493 ± 120.5 cells/mL, P < 0.0001) (Fig. 2B) . Of note, the major elevated subset of MDSCs was comprised of CD14 + CD15 -monocytic MDSCs, and the percentage of monocytic MDSCs was higher in IgG4-SC, as well as the cell count, when compared to PSC, AIH, or HCs (Fig. 2C) . Intriguingly, the expression of receptor RANK was elevated in peripheral MDSCs in IgG4-SC, and the expression was significantly higher than that in PSC (P = 0.0003), AIH (P = 0.0010), and HCs (P < 0.0001) (Fig. 2D) . Moreover, there was a positive correlation between serum levels of RANKL and frequency of MDSCs (R 2 = 0.4865, P < 0.0001) (Fig. 2E) . Taken together, our results demonstrate that activation of the RANKL-RANK pathway significantly correlated with MDSC accumulation in IgG4-SC patients.
CoRRelatioN oF RaNKl aND MDSCs WitH DiSeaSe SeVeRity
There was a negative association between serum RANKL and gamma-glutamyltransferase levels (R 2 = 0.1633, P = 0.0365) (Supporting Fig. S2B ). Moreover, the percentage of MDSCs was negatively correlated with total bilirubin (R 2 = 0.1664, P = 0.0347) (Supporting Fig. S2F ). Our data indicate that serum RANKL levels correlate with disease severity.
RaNKl iNDUCeS MDSC eXpaNSioN aND eXpReSSioN oF CCR5, CXCR3, aND CX3CR1
We directly evaluated the role of the RANKL-RANK signaling pathway on MDSC induction using PBMCs from healthy donors. PBMCs were cultured in the presence of serial concentrations of recombinant RANKL for up to 7 days based on pilot work to define optimal culture conditions. FACS analysis demonstrated a high frequency of CD11b + CD33 + HLA-DR −/lo
MDSCs induction among RANKL-treated PBMCs on day 5 (Fig. 3A ) and day 7 ( Supporting Fig. S3A ), which was significantly higher than that in the untreated group. We also analyzed the effect of RANKL on other cells, and there were no significant expansions when compared with the untreated group or the GM-CSF and/or IL-6-treated group (Supporting Fig. S4 ). Consistent Confocal microscopy results demonstrate colocalization of the B-cell markers CD19, CD38, and CD138 with RANKL using liver tissue of IgG4-SC patients. Bars reflect the mean ± SD. *P < 0.05, **P < 0.01, ****P < 0.0001. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; hpf, high-power field; NC, normal controls. with these data, the expansion of MDSCs was positively correlated with RANKL concentration (R 2 = 0.3235, P < 0.0001) (Fig. 3B) ; 25 ng/mL of recombinant human RANKL induced MDSCs not inferior to GM-CSF and/or IL-6-treated positive controls at day 5 (Fig. 3C) . Therefore, based upon these data, we used 25 ng/mL RANKL culturing for subsequent studies.
To verify the costimulation effect of cytokines on MDSC expansion, we treated PBMCs with Expression of chemokine receptors on MDSCs was induced after culture with RANKL or GM-CSF+RANKL; no difference was detected between two groups. Bars reflect the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. a combination of RANKL, GM-CSF, and IL-6 to expand MDSCs. On day 5, all groups demonstrated similar and significant expansion of MDSCs (Supporting Fig. S3B ), suggesting the noninferiority of RANKL alone to expand MDSCs. Thence we compared the expression of chemokine receptors on MDSCs in IgG4-SC and HCs. We demonstrated that the expression of CCR2, CCR5, CCR6, CXCR3, and CX3CR1 (30) (31) (32) (33) on MDSCs was significantly increased in IgG4-SC compared to HCs ( Fig.  3D; Supporting Fig. S3C,D) . To determine whether RANKL could induce chemokine receptor expression to affect the recruitment of MDSCs, we detected expression of chemokine receptors on PBMCs stimulated by RANKL with or without GM-CSF costimulation after culturing for 7 days. The expression of CCR5, CXCR3, and CX3CR1 was significantly induced in the RANKL-stimulated group (Fig. 3E,F) . Interestingly, no difference was observed in the effect of inducing chemokine receptor expression between the RANKL plus GM-CSF-costimulated group and the RANKL-stimulated group (Fig. 3F) .
iNHiBitioN oF NF-κB SigNaliNg SUppReSSeS tHe RaNKliNDUCeD eXpaNSioN oF MDSCS aND No pRoDUCtioN
To verify the induction effect of RANKL, the fragment crystallizable region of RANK (RANK-Fc) was used in the culture medium to neutralize RANKL. No expansions of MDSCs were observed on day 3 and day 7, supporting the thesis that RANKL induces MDSCs through RANKL-RANK interaction (Fig. 4A) . The interaction of RANK and its ligand (RANKL) promotes NF-κB activation. (19, 34) To further investigate whether NF-κB signaling is critical for MDSC expansion and activation, NF-κB inhibitors were added in the induction medium. Significantly fewer CD11b + CD33 + HLA-DR −/lo cells were induced in the presence of inhibitor of the NF-κB pathway BAY 11-7082 on both day 3 and day 7 (Fig. 4B) , and the same effects were observed in cells treated with CAPE (Fig. 4C) . Moreover, this inhibition could not be rescued with subsequent RANKL treatment (Fig. 4B,C) . In addition, NO production could be suppressed using the NF-κB signaling pathway inhibitors BAY 11-7082 (Supporting Fig. S6A ) and CAPE (Supporting Fig. S6B ).
RaNKl-iNDUCeD MDSCS poSSeSS iMMUNoSUppReSSiVe FUNCtioNS aND FaVoR t-Cell DiFFeReNtiatioN toWaRD th2
To determine whether RANKL-induced MDSCs exhibited similar immunosuppressive functions compared with the GM-CSF/IL-6-induced positive controls, we examined the inhibitory effects of RANKL-induced MDSCs on T-cell proliferation in vitro. The immunosuppressive effects of MDSCs were determined when RANKL-induced MDSCs were cocultured with Pan T cells (at ratios of 1:8 and 1:4); proliferation of naive T cells was measured by 5-(and 6-)carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution and flow cytometry 72 hours later. Treatment with RANKL for 5 days expanded MDSCs with similar immunosuppressive abilities compared to the GM-CSF and/or IL-6-stimulated groups (Fig. 5A,B) . Moreover, PBMCs induced by RANKL combined with GM-CSF demonstrated higher inhibitory effects on T-cell proliferation (Fig. 5B) . Although there was no obvious elevation of ROS produced by MDSCs in the RANKL-induced group (not shown), DAF-FM diacetate staining, which is an NO indicator, displayed an increase in the RANKL-induced group when compared with the GM-CSF and/or IL-6-stimulated groups or untreated group (Fig. 5C,E) . Consistent with flow-cytometric analysis, MDSC and T-cell coculture resulted in a significant increase in the level of NO from the RANKL-induced group with or without GM-CSF combination (Fig. 5D) .
To determine the suppressive abilities of MDSCs on T-cell responses, we cocultured naive CD4 + T cells with RANKL-treated MDSCs under either Th1 or Th2 polarization culture conditions for 7 days (Fig.  6A) . CD4 + T cells cocultured with GM-CSF/IL-6-induced MDSCs demonstrated decreased secretion of IL-4, whereas CD4 + T cells cocultured with RANKLinduced MDSCs led to a significantly elevated IL-4 level, which was even higher than the CD4 + T-cell alone (no MDSC) group (Fig. 6C) . This effect could be suppressed by a specific iNOS inhibitor, 1400w, other than superoxide dismutase (which is an ROS inhibitor) (Fig. 6D,E) . All of the above findings suggested that MDSCs favor Th-cell differentiation toward Th2 through iNOS.
Discussion
We report that activation of the RANKL-RANK pathway induces MDSC-mediated selective modulation of T-cell differentiation and suggest an inflammatory interaction between B cells and MDSCs in patients with IgG4-SC. Our data indicate that RANKL induces the expansion and activation of MDSCs were treated with the NF-kB pathway inhibitor BAY 11-7082, and expansion folds were determined on day 3 and day 7. (C) Expansion folds of MDSC treatment with another NF-kB pathway inhibitor, CAPE, on day3 and day 7 were detected; significantly fewer HLA-DR −/lo CD11b + CD33 + cells were induced in the presence of inhibitors of the NF-κB pathway. Importantly, this inhibition could not be rescued with subsequent RANKL treatment (B,C). Bars reflect the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: DMSO, dimethyl sulfoxide; Fc, fragment crystallizable (region).
MDSCs in vitro and highlight the clinical association of MDSCs and RANKL. Rituximab-induced B-cell depletion results in rapid clinical and histological improvement accompanied by declines in serum IgG4 concentration, supporting a role of B cells in IgG4-RD. (35, 36) Expanded CD4 + T cells, Th2 cells, and elevated circulating plasmablasts (IgG4 + plasma cells) have been observed in active IgG4-RD. (4, 5, 37, 38) Activated IgG4 + B cells and plasma cells may contribute to the pathogenesis of IgG4-SC either directly through autoantibody production or indirectly through activation of pathogenic CD4 + T cells, presumably serving as effective antigen-presenting cells.
(2) Our study identified B cells, especially plasma cells, as the cellular source of RANKL in IgG4-SC, which activated MDSCs and may be a potential therapeutic target to inhibit the development of IgG4-SC. It had been reported that IgGs in patients with IgG4-RD, including IgG1 and IgG4, have pathogenic effects on neonatal mouse pancreas and salivary gland. (39) Interestingly, our study demonstrated that serum levels of IgG and IgG4 correlated with levels of RANKL and, further, that RANKL-targeted therapeutics could be an effective treatment for IgG4-SC and reduce pathogenic IgG4.
Our data demonstrate an increase of CD11b + CD33 + HLA-DR −/lo MDSCs and the receptor RANK in the periphery of IgG4-SC. This is consistent with other reports in immune-mediated diseases (12, 40, 41) that in response to chronic stimulation MDSC expansion was initiated and converted into immune-suppressive cells. RANKL induces the expansion and suppressive activity of MDSCs through interacting with RANK and activating the NF-κB pathway. Of note, the NF-κB pathway has been implicated in the suppressive function of MDSCs, and our results further these data and propose that the NF-κB pathway promotes the expansion of MDSCs because inhibitors of the NF-κB signaling pathway effectively reduce the induction of MDSCs by RANKL. One unresolved issue on the immunobiology of MDSCs is whether the accumulation of MDSCs requires one or two signals. (42) IL-6 can initiate this process and activates cells for conversion into immune-suppressive cells. (12, 43) Our work suggests the noninferior ability of RANKL alone to expand MDSCs. However, there are limitations to our study. The availability of fresh organ tissues from patients with IgG4-SC was limited, and we could not analyze the immunobiology of MDSCs in inflamed liver. To address this question, we analyzed the chemokine receptors on MDSCs and demonstrate that RANKL induces the expression of CCR5, CXCR3, and CX3CR1, which should facilitate the recruitment of MDSCs. Nonetheless, future studies should attempt direct target tissue analysis.
It is thought that storiform fibrosis results from the induction of an excessive, aberrant repair process mediated by a Th2-dependent, profibrotic pathway possibly facilitated by activated macrophages and myofibroblasts. (44) MDSCs have been implicated in the inhibition of interferon through the production of NO in murine immunological hepatic injury models. (45) In addition, MDSCs have been demonstrated to skew allogeneic T cells toward Th2 cells upregulating Th2-specific cytokines in graft-versus-host disease. (46) MDSCs may promote the reciprocal differentiation between Th1 and Th2 cells in IgG4-SC. In our study, RANKL-induced MDSCs exerted suppressive function on T cells through production of NO, which has been demonstrated to induce selective suppression on Th1 cells and thereby promote a Th2 response. (47) Our study demonstrated that RANKL-induced MDSCs exert directional modulation on the proliferation and differentiation of CD4 + T cells, which play a role in the development of this fibroinflammatory disease. (7, 48) Our data emphasize that the accumulation of MDSCs participates in IgG4-RD. B cells producing RANKL facilitate the expansion and activation of MDSCs to alter the balance of CD4 + Th cell differentiation, thus facilitating the persistence of the fibroinflammatory process.
In conclusion, the data presented here provide insight into the selective immunosuppressive ability of MDSCs during chronic inflammation and the pathogenesis of IgG4-RD. Rigorous dissection of the mediators involved may offer novel therapies from an immunoregulatory perspective.
